Human Papillomavirus (HPV) Genotyping Detection: Technical Overview, Methods, and Clinical Applicati

Human Papillomavirus (HPV) genotyping detection is a molecular diagnostic technique that identifies specific HPV genotypes in clinical specimens, distinguishing high-risk types associated with cervical and other anogenital cancers from low-risk types linked to benign warts. This article provides a comprehensive technical overview of HPV genotyping, covering sample types, detectable genotypes, laboratory methods, clinical applications, and frequently asked questions for healthcare professionals and laboratory practitioners.

Technical Overview

Human Papillomavirus (HPV) is a small, non-enveloped, double-stranded DNA virus belonging to the Papillomaviridae family. To date, more than 200 HPV genotypes have been identified, of which approximately 40 infect the anogenital mucosa. Based on their oncogenic potential, HPV genotypes are classified into high-risk (HR) and low-risk (LR) categories. High-risk genotypes, including HPV 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66, and 68, are etiologically responsible for nearly all cases of cervical cancer as well as a substantial proportion of anal, vulvar, vaginal, penile, and oropharyngeal cancers. Low-risk genotypes, primarily HPV 6 and 11, are associated with condyloma acuminata (genital warts) and low-grade squamous intraepithelial lesions.

HPV genotyping detection refers to nucleic acid-based assays that not only detect the presence of HPV DNA but also determine the specific genotype or genotype group present in a clinical sample. Compared with pooled high-risk HPV testing, genotyping provides enhanced clinical value through individual risk stratification. For example, HPV 16 and HPV 18 carry a significantly higher risk of cervical intraepithelial neoplasia grade 3 or worse (CIN3+) than other high-risk types, and current guidelines recommend direct colposcopic referral for women positive for these two genotypes. Genotyping also supports patient follow-up by distinguishing persistent infection from reinfection with a different genotype, and it enables population-level monitoring of vaccine impact on genotype-specific prevalence.

Testing Samples

HPV genotyping can be performed on a variety of clinical specimens. Proper sample collection, preservation, and transport are critical to ensure analytical sensitivity and validity of results.

Cervical Exfoliated Cell Specimens

Cervical samples collected by clinicians using cytobrushes or spatulas placed in preservative solution represent the standard specimen type for cervical cancer screening. Residual material from liquid-based cytology vials is widely used, allowing simultaneous cytology and HPV testing. Sampling should avoid collection during menstruation, within 24 hours of sexual intercourse, or following vaginal medication, douching, or gynecological procedures.

Vaginal Self-Collected Specimens

Self-collected vaginal swabs have demonstrated clinical performance comparable to clinician-collected cervical samples for HPV DNA testing in multiple validation studies. Self-sampling is increasingly used to improve screening coverage among under-screened populations and in resource-limited settings, supported by validated PCR-based genotyping assays.

Anal and Perianal Swabs

Anal swabs are indicated for anal cancer screening in high-risk populations, including men who have sex with men, HIV-positive individuals, and patients with a history of anogenital condyloma or cervical neoplasia.

Oropharyngeal and Oral Swabs

Gargle rinses and oropharyngeal swabs can be tested to detect oral HPV infection, which is epidemiologically linked to oropharyngeal squamous cell carcinoma, particularly among middle-aged adults.

Male Genital Specimens

Penile glans, coronal sulcus, foreskin, and urethral swabs may be collected for research purposes or clinical evaluation of male partners in HPV-related disease management, although routine male HPV screening is not currently recommended.

Tissue Specimens

Fresh biopsy tissue and formalin-fixed paraffin-embedded (FFPE) tissue blocks from cervical, anal, or oropharyngeal lesions can be subjected to HPV genotyping to confirm the etiology of detected lesions and support pathological diagnosis.

Testing Items

Commercial and laboratory-developed HPV genotyping assays typically cover the clinically significant genotypes grouped into high-risk and low-risk categories. A common comprehensive panel detects up to 27 genotypes in a single reaction.

• High-risk genotypes (14 to 18 types): HPV 16, 18, 26, 31, 33, 35, 39, 45, 51, 52, 53, 56, 58, 59, 66, 68, 73, and 82, with HPV 16 and 18 individually reported due to their high oncogenic potential.
• Low-risk genotypes (6 to 11 types): HPV 6, 11, 40, 42, 43, 44, and 81 (also designated CP8304 in certain assay panels), which are predominantly associated with genital warts and low-grade lesions.
• Extended genotyping: Some platforms offer partial genotyping (HPV 16/18 with pooled reporting of other high-risk types) or full individual reporting of all targets, depending on clinical requirements.
• Result reporting: Reports generally specify the genotype(s) detected, the risk category, the analytical method used, internal control status, and interpretive comments aligned with current clinical management guidelines.

Testing Methods

Multiple molecular platforms have been developed for HPV genotyping, each with distinct principles, throughput, and clinical performance characteristics.

PCR Reverse Dot Blot Hybridization

This method amplifies HPV DNA using consensus primers targeting the L1 region (such as PGMY09/11 or GP5+/6+ primer sets), followed by hybridization of biotin-labeled amplicons to genotype-specific oligonucleotide probes immobilized on membrane strips. Colorimetric detection yields visible bands corresponding to the genotypes present. It enables simultaneous detection of more than 20 genotypes and is widely adopted in clinical laboratories due to its balanced cost and comprehensive coverage.

Flow-Through Hybridization (Gene Chip)

Flow-through hybridization accelerates probe-target hybridization by actively driving the denatured amplicon through a porous membrane coated with immobilized genotype-specific probes, dramatically reducing hybridization time. This low-density gene chip format provides high-throughput genotyping with results available within one working day.

Real-Time Fluorescent Quantitative PCR

Genotype-specific or multiplex real-time PCR assays use fluorescent-labeled probes or melting curve analysis to identify HPV genotypes with high analytical sensitivity and a broad dynamic range. Closed-tube amplification and detection minimize contamination risk, making the method well suited for automated, high-volume screening workflows.

Multiplex PCR with Capillary Electrophoresis

Multiplex fluorescent PCR combined with capillary electrophoretic fragment analysis assigns genotypes based on amplicon size and fluorescence channel, offering precise discrimination of multiple targets and objective, software-driven result interpretation.

Next-Generation Sequencing (NGS)

HPV sequencing approaches, including targeted amplicon sequencing and metagenomic sequencing, provide unbiased genotype identification, detection of mixed infections, and characterization of viral variants and integration events. NGS is primarily used in research, epidemiological surveillance, and reference laboratory settings.

Mass Spectrometry-Based Genotyping

Matrix-assisted laser desorption/ionization time-of-flight mass spectrometry (MALDI-TOF MS) genotyping distinguishes HPV types by the molecular weight of extension products, enabling highly multiplexed, high-throughput analysis with excellent specificity.

Applications

HPV genotyping detection has become an integral component of cervical cancer prevention programs and the clinical management of HPV-associated diseases.

• Cervical cancer screening: Primary HPV screening or co-testing with cytology in women aged 25 to 65 years, with HPV 16/18-positive results triaged directly to colposcopy and other high-risk genotypes managed by reflex cytology.
• Triage of abnormal cytology: Genotyping of women with atypical squamous cells of undetermined significance (ASC-US) helps determine the need for colposcopic evaluation.
• Post-treatment surveillance: Testing at 6 to 12 months after treatment of cervical precancerous lesions serves as a test of cure, identifying residual or recurrent disease.
• Distinguishing persistent infection: Serial genotyping differentiates persistent infection with the same genotype, a strong predictor of progressive disease, from transient infections or new acquisitions.
• Vaccine evaluation and surveillance: Population-based genotyping monitors genotype-specific prevalence and demonstrates the herd immunity and cross-protection effects of prophylactic vaccination programs.
• Non-cervical disease management: Evaluation of anal, oropharyngeal, penile, and vulvovaginal lesions, particularly in immunocompromised patients and other high-risk groups.
• Research applications: Support for epidemiological studies, natural history investigations, clinical trials, and development of therapeutic and diagnostic biomarkers.

FAQ

Does a positive HPV genotyping result mean I have cancer? No. A positive result indicates the presence of HPV DNA, which most commonly reflects a transient infection that the immune system clears naturally within one to two years. Only persistent infection with high-risk genotypes carries an elevated risk of precancerous changes, which, if identified, are highly treatable.

What is the difference between genotyping and pooled high-risk HPV testing? Pooled assays report only the presence or absence of any high-risk HPV without identifying the type, whereas genotyping specifies exactly which genotype is present, enabling individualized risk stratification and longitudinal follow-up.

Who should undergo HPV genotyping? Routine HPV testing, including partial or full genotyping, is recommended for women aged 25 years and older as part of cervical cancer screening, either as primary HPV testing every five years or co-testing with cytology every five years, in accordance with regional guidelines.

How should patients prepare for sampling? Patients should avoid sexual intercourse, vaginal medications, douching, and gynecological examinations within 24 to 48 hours before sampling, and collection should ideally be scheduled outside the menstrual period. Fasting is not required.

How long does it take to obtain results? Most PCR-based genotyping assays can be completed within one to three working days after the specimen reaches the laboratory, depending on the platform and laboratory workflow.

What does a negative result mean? A negative result indicates that none of the genotypes targeted by the assay were detected at or above the analytical detection limit. The risk of significant cervical disease in the near term is very low, but regular screening according to age-appropriate schedules should continue.

Can HPV genotyping detect infections in men? Yes, the assays can be applied to male genital, anal, or oral specimens; however, routine HPV screening of men is not currently recommended by major guidelines, and testing in men is generally reserved for clinical evaluation or research purposes.